EDIT Editas Medicine, Inc. - Common Stock
$3,19
Precio · Ago 19, 2026
Fundamentales a fecha de Ago 5, 2026
Rango 52S
$2–$5
53% of range
Calificación del Analista
BUY
18 analysts
Precio Objetivo
$6
+88% upside
P/E (TTM)
-1.8
ROE
-688.8%
Margen de Beneficio Neto
-395.0%
Acerca de Editas Medicine, Inc. - Common Stock Descripción general de la empresa de Wikipedia
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Leer más
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
History
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures. The name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9.
In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors. it went public on 2 February 2016, via a $94 million initial public offering.
Editas entered into a strategic collaboration with Juno Therapeutics in 2015 to create a chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics. Juno was later acquired by Celgene, which was in turn acquired by Bristol Myers Squibb.
The company announced in 2015 that it was planning a clinical trial using CRISPR gene editing techniques to treat Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness. On 30 November 2018, the FDA gave permission to start the trials, under the investigational name EDIT-101 (also known as AGN-151587). In September 2021, a statement from Editas claimed that preliminary results from clinical trials were promising and support clinical benefits of EDIT-101 treatment.
In March 2020, Editas, in partnership with Allergan, was the first to use CRISPR to try to edit DNA inside a person's body (in vivo). As part of the clinical trial, a patient who was nearly blind as a result of Leber's congenital amaurosis received an intravitreal injection containing a harmless virus carrying CRISPR gene-editing instructions. Five months later, Editas reworked its deal with Allergan's owner AbbVie and regained full rights to their range of eye disease treatment therapies, including EDIT-101 for the treatment of LCA10.
In 2019, the company was building new chemistry facilities in Boulder, Colorado.
Katrine Bosley was CEO until 2019, when she was replaced by board member Cynthia Collins. Collins was replaced in 2021 by James Mullen, who had been board chairman. Gilmore O'Neill, former CMO of Sarepta Therapeutics, became CEO on June 1, 2022, with Mullen staying on as executive chairman of the board.
On December 12, 2024, Editas ended the development of reni-cel and laid off 65% of its employees.
Research
Editas works with two different CRISPR nucleases, Cas9 and Cas12a.
EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, currently in clinical trials.
EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia. In 2019 the firm reported early success in research on the drug;. In December 2020, it filed an IND application for treatment of sickle cell disease. In January 2021, it said it had received clearance from the FDA for phase 1 safety studies.
== References ==
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
EDIT Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$3.19
Capitalización Bursátil
$312M
P/E (TTM)
-1.8
BPA (TTM)
$-1.80
Ingresos (TTM)
$41M
Rendimiento div.
—
ROE
-688.8%
Deuda/Capital
2.1
Rango 52S
$2 – $5
EDIT Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$41M
2016-12-31
→
2025-12-31
BPA
$-1.80
2019-12-31
→
2025-12-31
Flujo de caja libre
$-166M
2016-12-31
→
2025-12-31
Márgenes
-395.0%
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
EDIT
Mediana de Pares
P/E (TTM)
-1.8
17.4
P/S (TTM) (P/V (TTM))
7.7
52.3
P/B (P/C)
11.4
4.8
EV / EBITDA
-1.4
—
Price / FCF (Precio / FCF)
-1.9
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
EDIT
Mediana de Pares
Operating Margin (Margen Operativo)
-394.9%
—
Net Profit Margin (Margen de Beneficio Neto)
-395.0%
-670.1%
ROA
-60.6%
-41.1%
ROE
-688.8%
-52.6%
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
EDIT
Mediana de Pares
Debt / Equity (Deuda / Patrimonio)
2.1
—
Current Ratio (Ratio corriente)
3.5
7.7
Quick Ratio (Ratio Rápido)
3.5
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
EDIT
Mediana de Pares
Revenue YoY (Ingresos interanuales)
25.4%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
27.2%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
-14.9%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
EDIT
Mediana de Pares
EDIT Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
18 analistas
- Compra fuerte 4 22,2%
- Compra 8 44,4%
- Mantener 4 22,2%
- Venta 2 11,1%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
8 analistas · 2026-08-16
Mediana
$5.00
Ahora
$3.19
Mín
$1.00
Máx
$15.00
Objetivo mediano
$5.00
+57,0%
Objetivo medio
$6.00
+88,4%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
-0.03%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $-0.15 | $-0.28 | 0.13% |
| 31 de marzo de 2026 | $-0.26 | $-0.27 | 0.01% |
| 31 de diciembre de 2025 | $-0.06 | $-0.26 | 0.20% |
| 30 de septiembre de 2025 | $-0.28 | $-0.30 | 0.02% |
| 30 de junio de 2025 | $-0.63 | $-0.38 | -0.25% |
| 31 de marzo de 2025 | $-0.92 | $-0.60 | -0.32% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | — |
| LRMR | $317M | -2.2 | — | — | -167.4% | — |
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | — |
| RZLT | $388M | -4.6 | — | — | -56.9% | — |
| BNTC | $307M | -11.1 | — | — | -43.8% | — |
| CMPX | $958M | — | — | — | -45.9% | — |
| PROK | — | — | 1075.0% | -7725.2% | 6.9% | — |
| FENC | $263M | -22.6 | -6.1% | -21.8% | -69.6% | — |
| LXEO | $725M | -5.3 | — | — | -51.9% | — |
| CAPR | $1.66B | -12.8 | -11.6% | — | -51.1% | — |
| FHTX | $306M | -4.6 | 36.8% | -240.3% | 80.2% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 13
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| R&D Expense | $90M | $199M | $178M | $175M | $143M | $158M | $97M | $91M | $83M | $57M | |
| SG&A Expense | $50M | $72M | $70M | $71M | $76M | $68M | $65M | $55M | $51M | $46M | |
| Operating Expenses | $201M | $283M | $247M | $246M | $219M | $226M | $161M | $146M | $134M | $103M | |
| Operating Income | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M | |
| Other Non-op | $-2M | $-3.0K | $-2M | $0 | $37.0K | $16M | $-137.0K | $328.0K | $587.0K | $-57.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| EPS (Basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| Shares (Basic) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| Shares (Diluted) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| EBITDA | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M |
Balance general 24
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $147M | $132M | $124M | $142M | $204M | $140M | $238M | $135M | $147M | $185M | |
| Short-term Investments | $0 | $138M | $199M | $203M | $296M | $262M | $219M | $234M | $183M | · | |
| Receivables | $15M | $16M | $10M | $5M | $267.0K | $6M | $418.0K | $30.0K | $679.0K | $88.0K | |
| Prepaid Expense | $2M | $3M | $8M | $7M | $7M | $11M | $6M | $6M | $2M | $2M | |
| Current Assets | $164M | $289M | $341M | $357M | $507M | $419M | $464M | $375M | $332M | $187M | |
| PP&E (Net) | $4M | $14M | $12M | $16M | $17M | $14M | $11M | $40M | $39M | $40M | |
| PP&E (Gross) | $32M | $46M | $38M | $37M | $33M | $25M | $18M | $47M | $44M | $42M | |
| Accum. Depreciation | $28M | $32M | $26M | $22M | $16M | $11M | $7M | $7M | $4M | $2M | |
| Other Non-current Assets | $3M | $5M | $9M | $5M | $7M | $5M | $5M | $5M | $2M | $2M | |
| Total Assets | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Accounts Payable | $3M | $5M | $8M | $10M | $5M | $6M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $33M | $46M | $35M | $31M | $20M | $24M | $22M | $13M | $11M | $17M | |
| Current Liabilities | $46M | $77M | $63M | $60M | $47M | $58M | $60M | $36M | $37M | $33M | |
| Capital Leases | $12M | $20M | $24M | $33M | $16M | $19M | $23M | $32M | $33M | $35M | |
| Other Non-current Liabilities | $3M | $3M | $2M | $0 | · | $28M | $1.0K | $293.0K | $317.0K | $396.0K | |
| Total Liabilities | $159M | $207M | $150M | $154M | $124M | $179M | $246M | $184M | $165M | $95M | |
| Long-term Debt | $59M | $57M | $0 | · | · | · | · | · | · | · | |
| Total Debt | $59M | $57M | · | · | · | · | · | · | · | · | |
| Common Stock | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.63B | $-1.47B | $-1.23B | $-1.08B | $-858M | $-665M | $-549M | $-416M | $-306M | $-186M | |
| AOCI | $0 | $268.0K | $198.0K | $-4M | $-493.0K | $-46.0K | $107.0K | $-29.0K | $-76.0K | · | |
| Stockholders' Equity | $27M | $134M | $349M | $361M | $554M | $394M | $262M | $236M | $208M | $135M | |
| Liabilities + Equity | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Shares Outstanding | 97,866,996 | 82,734,696 | 81,767,263 | 68,847,382 | 68,435,257 | 62,563,457 | 54,355,798 | 48,758,951 | 44,507,960 | 35,818,131 |
Flujo de Efectivo 10
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $10M | $21M | $20M | $29M | $43M | $23M | $27M | $27M | $23M | $17M | |
| Restructuring | · | $12M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $-165M | $-210M | $-132M | $-177M | $-164M | $-180M | $-41M | $-46M | $-9M | $-50M | |
| CapEx | $607.0K | $9M | $5M | $4M | $8M | $7M | $6M | $5M | $2M | $3M | |
| Investing Cash Flow | $139M | $162M | $-4M | $114M | $-54M | $-141M | $12M | $-53M | $-184M | $-3M | |
| Stock Issued | $43M | $0 | $117M | $0 | $249M | $204M | $116M | $77M | $154M | $97M | |
| Net Stock Activity | $43M | $0 | $117M | · | $249M | $204M | $116M | $77M | $154M | $97M | |
| Financing Cash Flow | $40M | $56M | $118M | $1M | $282M | $224M | $132M | $87M | $155M | $97M | |
| Net Change in Cash | $14M | $8M | $-18M | $-62M | $64M | $-96M | $103M | $-12M | $-39M | $43M | |
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M | $-187M | $-47M | $-50M | $-11M | $-53M |
Rentabilidad 5
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| Net Margin | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | · | · | |
| EBITDA Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| ROA | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -40.0% | -51.3% | |
| ROE | -688.8% | -153.0% | -43.2% | -56.9% | -33.8% | -27.8% | -56.6% | -47.7% | -70.2% | -377.5% |
Liquidez y Solvencia 4
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 | 7.2 | 7.7 | 10.4 | 9.1 | 5.7 | |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 | 7.0 | 7.6 | 10.3 | 9.0 | 5.6 | |
| Debt / Equity | 2.1 | 0.4 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 2.0 | 0.4 | · | · | · | · | · | · | · | · |
Eficiencia 2
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | · | · | |
| Receivables Turnover | 2.6 | 2.4 | 10.2 | 7.3 | 8.1 | 28.1 | 91.7 | 90.1 | · | · |
Tasas de Crecimiento 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 25.4% | -58.6% | 296.3% | -22.8% | -71.9% | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.2% | 8.2% | -4.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -14.9% | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 14
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| Net Income TTM | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| Market Cap | $201M | $105M | $828M | $611M | $1.82B | $4.39B | $1.61B | $1.11B | $1.37B | $581M | |
| Enterprise Value | $113M | $-107M | · | · | · | · | · | · | · | · | |
| P/E | -1.1 | -0.4 | -5.0 | -2.8 | -9.3 | -35.4 | -11.0 | · | · | · | |
| P/S | 5.0 | 3.3 | 10.6 | 31.0 | 71.1 | 48.3 | 78.4 | 34.7 | 99.6 | 96.0 | |
| P/B | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | 6.1 | 4.7 | 6.6 | 4.3 | |
| P / Tangible Book | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | · | · | · | · | |
| P / Cash Flow | -1.2 | -0.5 | -6.3 | -3.4 | -11.1 | -24.4 | -39.6 | -24.3 | -145.2 | -11.6 | |
| P / FCF | -1.2 | -0.5 | -6.1 | -3.4 | -10.6 | -23.5 | -34.4 | -22.0 | -119.2 | -10.9 | |
| EV / EBITDA | -0.7 | 0.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -0.7 | 0.5 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 2.8 | -3.3 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -87.8% | -226.8% | -19.9% | -36.2% | -10.7% | -2.8% | -9.0% | · | · | · |
Estado de resultados 12
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $3M | $25M | $8M | $4M | $5M | $31M | $61.0K | $513.0K | $1M | $60M | $5M | $3M | $10M | $7M | $42.0K | |
| R&D Expense | $20M | $18M | $27M | $20M | $16M | $27M | $49M | $48M | $54M | $49M | $70M | $41M | $30M | $38M | $52M | $41M | |
| SG&A Expense | $12M | $10M | $11M | $12M | $13M | $13M | $16M | $18M | $18M | $19M | $14M | $15M | $17M | $23M | $18M | $16M | |
| Operating Expenses | $30M | $28M | $32M | $32M | $55M | $81M | $77M | $66M | $72M | $68M | $84M | $55M | $47M | $61M | $70M | $58M | |
| Operating Income | $-19M | $-25M | $-8M | $-25M | $-52M | $-76M | $-47M | $-66M | $-72M | $-67M | $-24M | $-50M | $-44M | $-51M | $-63M | $-58M | |
| Other Non-op | $17.0K | $-113.0K | $-5.0K | $-1.0K | $-2M | $-425.0K | $-3.0K | $-5.0K | $-1.0K | $6.0K | $-13.0K | $0 | $-7.0K | $-2M | $-2.0K | $1.0K | |
| Net Income | $-18M | $-25M | $-6M | $-25M | $-53M | $-76M | $-45M | $-62M | $-68M | $-62M | $-19M | $-45M | $-40M | $-49M | $-61M | $-56M | |
| EPS (Basic) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| EPS (Diluted) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| Shares (Basic) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| Shares (Diluted) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| EBITDA | $-19M | $-25M | · | $-25M | $-52M | $-76M | · | $-66M | $-72M | $-67M | · | $-50M | $-44M | $-51M | · | $-58M |
Balance general 24
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $124M | $147M | $166M | $139M | $139M | $132M | $96M | $64M | $69M | $124M | $83M | $221M | $129M | $142M | $211M | |
| Short-term Investments | $30M | · | $0 | $0 | $40M | $82M | $138M | $169M | $215M | $227M | $199M | $267M | $211M | $189M | · | $209M | |
| Receivables | $3M | $3M | $15M | $8M | $588.0K | $510.0K | $16M | $126.0K | $244.0K | $245.0K | $10M | $2M | $2M | $242.0K | · | $120.0K | |
| Prepaid Expense | $4M | $2M | $2M | $3M | $4M | $3M | $3M | $6M | $7M | $9M | $8M | $7M | $7M | $6M | · | $7M | |
| Current Assets | $218M | $128M | $164M | $177M | $183M | $225M | $289M | $271M | $286M | $306M | $341M | $359M | $441M | $324M | · | $427M | |
| PP&E (Net) | $3M | $3M | $4M | $4M | $5M | $8M | $14M | $15M | $14M | $13M | $12M | $12M | $13M | $13M | · | $15M | |
| PP&E (Gross) | $29M | $29M | $32M | $32M | $31M | $36M | $46M | $46M | $43M | $41M | $38M | $37M | $36M | $35M | · | $36M | |
| Accum. Depreciation | $27M | $26M | $28M | $28M | $27M | $28M | $32M | $31M | $29M | $28M | $26M | $25M | $23M | $22M | · | $20M | |
| Other Non-current Assets | $3M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $8M | $9M | $9M | $6M | $5M | $7M | · | $8M | |
| Total Assets | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Accounts Payable | $5M | $4M | $3M | $3M | $7M | $5M | $5M | $12M | $14M | $8M | $8M | $10M | $8M | $9M | · | $7M | |
| Accrued Liabilities | $17M | $21M | $33M | $48M | $48M | $47M | $46M | $29M | $28M | $31M | $35M | $30M | $28M | $32M | · | $19M | |
| Current Liabilities | $68M | $40M | $46M | $62M | $66M | $73M | $77M | $72M | $74M | $66M | $63M | $59M | $55M | $57M | · | $42M | |
| Capital Leases | $9M | $11M | $12M | $14M | $15M | $18M | $20M | $22M | $21M | $22M | $24M | $25M | $27M | $29M | · | $9M | |
| Other Non-current Liabilities | $2M | $3M | $3M | $5M | $5M | $6M | $3M | $3M | $4M | $3M | $2M | · | · | · | · | · | |
| Total Liabilities | $132M | $145M | $159M | $188M | $191M | $201M | $207M | $152M | $153M | $146M | $150M | $144M | $142M | $147M | · | $116M | |
| Long-term Debt | $56M | $55M | $59M | $59M | $57M | $55M | $57M | · | · | · | $0 | · | · | · | · | · | |
| Total Debt | $56M | $55M | · | $59M | $57M | $55M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $15.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | · | $7.0K | |
| Retained Earnings | $-1.67B | $-1.65B | $-1.63B | $-1.62B | $-1.60B | $-1.54B | $-1.47B | $-1.42B | $-1.36B | $-1.29B | $-1.23B | $-1.21B | $-1.17B | $-1.13B | · | $-1.02B | |
| AOCI | $-6.0K | $0 | $0 | $0 | $15.0K | $88.0K | $268.0K | $522.0K | $-442.0K | $-326.0K | $198.0K | $-1M | $-2M | $-2M | · | $-4M | |
| Stockholders' Equity | $105M | $4M | $27M | $13M | $19M | $62M | $134M | $176M | $232M | $294M | $349M | $360M | $400M | $317M | $361M | $415M | |
| Liabilities + Equity | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Shares Outstanding | 97,866,996 | 97,866,996 | 97,866,996 | 93,264,421 | 87,388,425 | 83,709,536 | 82,734,696 | 82,538,624 | 82,429,514 | 82,234,951 | 81,767,263 | 81,668,796 | 81,616,909 | 68,993,591 | · | 68,761,729 |
Flujo de Efectivo 10
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $5M | $5M | $8M | $5M | $5M | $5M | $5M | $5M | $6M | |
| Restructuring | · | · | · | · | · | $53M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-30M | $-23M | $-36M | $-31M | $-50M | $-48M | $-51M | $-53M | $-57M | $-50M | $-22M | $-35M | $-39M | $-36M | $-42M | $-48M | |
| CapEx | $106.0K | $92.0K | $60.0K | $433.0K | $0 | $114.0K | $540.0K | $3M | $3M | $2M | $1M | $239.0K | $1M | $2M | $624.0K | $614.0K | |
| Investing Cash Flow | $-30M | $64.0K | $58.0K | $40M | $43M | $56M | $31M | $84M | $52M | $-5M | $63M | $-103M | $13M | $23M | $-28M | $89M | |
| Stock Issued | $117M | $0 | $17M | $17M | $7M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | · | · | $0 | · | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $118M | $0 | $17M | $17M | $7M | $-1M | $56M | $0 | $322.0K | $192.0K | $514.0K | $0 | $118M | $0 | $619.0K | $80.0K | |
| Net Change in Cash | $58M | $-23M | $-19M | $26M | $-150.0K | $7M | $36M | $31M | $-5M | $-54M | $41M | $-138M | $92M | $-13M | $-69M | $41M | |
| Free Cash Flow | · | $-23M | · | · | · | $-48M | · | · | · | $-52M | · | · | · | $-38M | · | · |
Rentabilidad 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| Net Margin | -153.3% | -882.4% | · | -333.0% | -1487.8% | -1633.5% | · | -101870.5% | -13178.8% | -5458.1% | · | -843.7% | -1395.6% | -497.8% | · | -132681.0% | |
| EBITDA Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| ROA | -8.1% | -12.1% | · | -9.5% | -17.9% | -21.6% | · | -14.9% | -14.6% | -13.7% | · | -8.7% | -7.2% | -9.0% | · | -8.9% | |
| ROE | -29.3% | -74.8% | · | -26.6% | -42.4% | -42.6% | · | -23.2% | -21.4% | -20.2% | · | -11.6% | -9.3% | -11.8% | · | -11.1% |
Liquidez y Solvencia 4
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.2 | · | 2.9 | 2.8 | 3.1 | · | 3.7 | 3.9 | 4.6 | · | 6.1 | 8.1 | 5.7 | · | 10.1 | |
| Quick Ratio | 3.1 | 3.2 | · | 2.8 | 2.7 | 3.0 | · | 3.7 | 3.8 | 4.5 | · | 6.0 | 8.0 | 5.6 | · | 9.9 | |
| Debt / Equity | 0.5 | 12.4 | · | 4.4 | 3.0 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 10.7 | · | 4.0 | 2.7 | 0.8 | · | · | · | · | · | · | · | · | · | · |
Eficiencia 2
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 7.2 | 1.8 | · | 1.8 | 8.6 | 12.3 | · | 0.0 | 0.4 | 4.7 | · | 4.2 | 1.9 | 12.2 | · | 0.2 |
Valoración (TTM) 14
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $26M | $19M | · | $16M | $9M | $6M | · | $7M | $10M | $19M | · | $18M | $19M | $23M | · | $19M | |
| Net Income TTM | $-122M | $-179M | · | $-217M | $-259M | $-268M | · | $-237M | $-215M | $-196M | · | $-190M | $-199M | $-209M | · | $-199M | |
| Market Cap | $317M | $242M | · | $324M | $192M | $97M | · | $281M | $385M | $610M | · | $637M | $672M | $500M | · | $842M | |
| Enterprise Value | $161M | $173M | · | $217M | $70M | $-69M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -2.5 | -1.2 | · | -1.3 | -0.7 | -0.4 | · | -1.2 | -1.7 | -2.9 | · | -3.0 | -2.9 | -2.4 | · | -4.2 | |
| P/S | 12.3 | 13.0 | · | 20.4 | 21.8 | 15.3 | · | 40.0 | 39.0 | 31.8 | · | 35.2 | 35.1 | 21.7 | · | 43.4 | |
| P/B | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Tangible Book | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Cash Flow | · | -10.5 | · | · | · | -2.0 | · | · | · | -12.2 | · | · | · | -14.0 | · | · | |
| P / FCF | · | -10.4 | · | · | · | -2.0 | · | · | · | -11.8 | · | · | · | -13.3 | · | · | |
| EV / EBITDA | -8.7 | -6.9 | · | -8.8 | -1.4 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | · | -7.5 | · | · | · | 1.4 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 6.2 | 9.3 | · | 13.7 | 8.0 | -10.9 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -40.7% | -84.6% | · | -74.4% | -141.8% | -280.2% | · | -84.5% | -57.6% | -34.8% | · | -33.7% | -34.8% | -41.9% | · | -23.7% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $41M | $32M | $78M | $20M | $26M |
| Margen Operativo % | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% |
| Beneficio neto | $-160M | $-237M | $-153M | $-220M | $-193M |
| EPS Diluido | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Deuda / Patrimonio | 2.1 | 0.4 | — | — | — |
| Ratio corriente | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 |
| Ratio Rápido | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $-166M | $-219M | $-137M | $-181M | $-172M |
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 239 declarantes · $327.2M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 41 (+2 vs trimestre anterior) | 22 (-4 vs trimestre anterior) | 76 (+20 vs trimestre anterior) | 42 (-9 vs trimestre anterior) | +75.4M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36 000 000 | 11 111 111 | 11,00% | Acciones |
| RA CAPITAL MANAGEMENT, L.P. | $28 800 360 | 8 889 000 | 8,80% | Acciones |
| Commodore Capital LP | $28 800 360 | 8 889 000 | 8,80% | Acciones |
| ADAR1 Capital Management, LLC | $28 800 360 | 8 889 000 | 8,80% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $19 897 929 | 6 141 336 | 6,08% | Acciones |
| Paradigm Biocapital Advisors LP | $18 100 665 | 5 586 625 | 5,53% | Acciones |
| Opaleye Management Inc. | $12 512 653 | 3 861 930 | 3,82% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $11 658 618 | 3 598 339 | 3,56% | Acciones |
| Woodline Partners LP | $11 519 810 | 3 555 497 | 3,52% | Acciones |
| Vivo Capital, LLC | $11 519 010 | 3 555 250 | 3,52% | Acciones |
| GordonMD Global Investments LP | $10 131 480 | 3 127 000 | 3,10% | Acciones |
| RENAISSANCE TECHNOLOGIES LLC | $7 999 298 | 2 468 919 | 2,45% | Acciones |
| Logos Global Management LP | $7 199 280 | 2 222 000 | 2,20% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $7 134 030 | 2 201 290 | 2,18% | Acciones |
| STATE STREET CORP | $7 101 442 | 2 191 803 | 2,17% | Acciones |
| GOLDMAN SACHS GROUP INC | $6 763 843 | 2 087 606 | 2,07% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $4 318 842 | 1 332 976 | 1,32% | Acciones |
| Seven Fleet Capital Management LP | $4 310 820 | 1 330 500 | 1,32% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $4 201 156 | 1 296 653 | 1,28% | Acciones |
| MARSHALL WACE, LLP | $4 044 048 | 1 248 163 | 1,24% | Acciones |
| D. E. Shaw & Co., Inc. | $3 715 178 | 1 146 660 | 1,14% | Acciones |
| KENNEDY CAPITAL MANAGEMENT LLC | $3 344 111 | 1 032 133 | 1,02% | Acciones |
| MACKENZIE FINANCIAL CORP | $2 844 856 | 878 042 | 0,87% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2 812 424 | 868 032 | 0,86% | Acciones |
| Nantahala Capital Management, LLC | $2 762 748 | 852 700 | 0,84% | Acciones |
| TWO SIGMA ADVISERS, LP | $2 509 405 | 1 224 100 | 0,77% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $2 407 158 | 742 950 | 0,74% | Acciones |
| BlackRock, Inc. | $1 813 920 | 559 852 | 0,55% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $1 616 750 | 498 997 | 0,49% | Acciones |
| Susquehanna Portfolio Strategies, LLC | $1 545 801 | 477 099 | 0,47% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 521 180 | 469 500 | 0,46% | Opción de compra |
| Eversept Partners, LP | $1 486 541 | 458 809 | 0,45% | Acciones |
| Casdin Capital, LLC | $1 441 800 | 445 000 | 0,44% | Acciones |
| PEAK6 LLC | $1 346 029 | 415 441 | 0,41% | Acciones |
| DIADEMA PARTNERS LP | $1 296 000 | 400 000 | 0,40% | Opción de compra |
| BIT Capital GmbH | $1 056 240 | 326 000 | 0,32% | Acciones |
| Cubist Systematic Strategies, LLC | $994 094 | 286 482 | 0,30% | Acciones |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $878 642 | 271 186 | 0,27% | Acciones |
| BANK OF AMERICA CORP /DE/ | $751 119 | 231 827 | 0,23% | Acciones |
| LPL Financial LLC | $748 813 | 231 115 | 0,23% | Acciones |
| Erste Asset Management GmbH | $736 000 | 230 000 | 0,22% | Acciones |
| IEQ CAPITAL, LLC | $705 623 | 217 785 | 0,22% | Acciones |
| Walleye Capital LLC | $595 703 | 183 859 | 0,18% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $558 900 | 172 500 | 0,17% | Opción de venta |
| CITADEL ADVISORS LLC | $557 604 | 172 100 | 0,17% | Opción de venta |
| DAFNA Capital Management LLC | $552 323 | 170 470 | 0,17% | Acciones |
| Mariner, LLC | $548 500 | 169 291 | 0,17% | Acciones |
| Green Alpha Advisors, LLC | $505 589 | 156 046 | 0,15% | Acciones |
| PEAK6 LLC | $497 340 | 153 500 | 0,15% | Opción de compra |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $490 555 | 151 406 | 0,15% | Acciones |
| BARCLAYS PLC | $476 030 | 146 923 | 0,15% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $464 187 | 187 930 | 0,14% | Acciones |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $445 030 | 137 355 | 0,14% | Acciones |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $408 240 | 126 000 | 0,12% | Acciones |
| Point72 Asset Management, L.P. | $405 758 | 125 234 | 0,12% | Acciones |
| RHUMBLINE ADVISERS | $380 421 | 117 417 | 0,12% | Acciones |
| JPMORGAN CHASE & CO | $376 528 | 117 665 | 0,12% | Acciones |
| JANE STREET GROUP, LLC | $374 473 | 115 578 | 0,11% | Acciones |
| FMR LLC | $348 384 | 107 526 | 0,11% | Acciones |
| HSBC HOLDINGS PLC | $314 481 | 97 062 | 0,10% | Acciones |
| Bank of New York Mellon Corp | $309 378 | 95 487 | 0,09% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $303 462 | 93 661 | 0,09% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $300 818 | 92 845 | 0,09% | Acciones |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $300 226 | 92 094 | 0,09% | Acciones |
| AMERICAN CENTURY COMPANIES INC | $300 011 | 92 596 | 0,09% | Acciones |
| CWM, LLC | $259 352 | 105 001 | 0,08% | Acciones |
| MORGAN STANLEY | $237 324 | 73 248 | 0,07% | Acciones |
| CITADEL ADVISORS LLC | $229 392 | 70 800 | 0,07% | Opción de compra |
| OSAIC HOLDINGS, INC. | $222 928 | 68 806 | 0,07% | Acciones |
| SEI INVESTMENTS CO | $221 188 | 68 268 | 0,07% | Acciones |
| Nuveen, LLC | $221 188 | 68 268 | 0,07% | Acciones |
| Joel Isaacson & Co., LLC | $220 787 | 68 144 | 0,07% | Acciones |
| JANE STREET GROUP, LLC | $218 376 | 67 400 | 0,07% | Opción de venta |
| SIMPLEX TRADING, LLC | $207 275 | 63 974 | 0,06% | Acciones |
| MetLife Investment Management, LLC | $182 140 | 56 216 | 0,06% | Acciones |
| CITIGROUP INC | $182 052 | 56 189 | 0,06% | Acciones |
| CITADEL ADVISORS LLC | $173 923 | 53 680 | 0,05% | Acciones |
| MML INVESTORS SERVICES, LLC | $168 765 | 52 088 | 0,05% | Acciones |
| GROUP ONE TRADING LLC | $163 131 | 50 349 | 0,05% | Acciones |
| Creative Planning | $147 653 | 45 572 | 0,05% | Acciones |
| China Universal Asset Management Co., Ltd. | $143 934 | 44 424 | 0,04% | Acciones |
| WINTON GROUP Ltd | $141 588 | 43 700 | 0,04% | Acciones |
| Vanguard Global Advisers, LLC | $138 876 | 42 863 | 0,04% | Acciones |
| CANADA PENSION PLAN INVESTMENT BOARD | $137 376 | 42 400 | 0,04% | Acciones |
| Graham Capital Management, L.P. | $134 369 | 41 472 | 0,04% | Acciones |
| Quinn Opportunity Partners LLC | $129 600 | 40 000 | 0,04% | Acciones |
| Invesco Ltd. | $128 178 | 39 561 | 0,04% | Acciones |
| Vanguard Personalized Indexing Management, LLC | $124 108 | 38 305 | 0,04% | Acciones |
| MERCER GLOBAL ADVISORS INC /ADV | $121 967 | 37 644 | 0,04% | Acciones |
| Balyasny Asset Management L.P. | $121 947 | 37 638 | 0,04% | Acciones |
| AXQ CAPITAL, LP | $118 104 | 36 452 | 0,04% | Acciones |
| Nuveen Asset Management, LLC | $113 934 | 89 712 | 0,03% | Acciones |
| SCS Capital Management LLC | $113 400 | 35 000 | 0,03% | Acciones |
| Police & Firemen's Retirement System of New Jersey | $109 749 | 33 873 | 0,03% | Acciones |
| Thrive Wealth Management, LLC | $108 540 | 33 500 | 0,03% | Acciones |
| TWO SIGMA SECURITIES, LLC | $107 367 | 33 138 | 0,03% | Acciones |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | $102 359 | 31 207 | 0,03% | Acciones |
| CAPTRUST FINANCIAL ADVISORS | $98 159 | 30 296 | 0,03% | Acciones |
| HORIZON KINETICS ASSET MANAGEMENT LLC | $89 683 | 27 680 | 0,03% | Acciones |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $88 339 | 27 265 | 0,03% | Acciones |
Informantes de la empresa 32 insiders · 13 directivos · 15 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO | 3 de junio de 2026 S | 248 313 | 0 | 1 | $-41 543 |
| MULLEN JAMES C | CEO | 3 de enero de 2022 S | 75 898 | 0 | 0 | $0 |
| Cynthia Collins | CEO | 9 de febrero de 2021 S | 43 760 | 0 | 0 | $0 |
| Katrine Bosley | President and CEO | 8 de enero de 2019 S | 1 204 966 | 0 | 0 | $0 |
| Michelle Robertson | Chief Financial Officer | 11 de enero de 2022 S | 31 462 | 0 | 0 | $0 |
| Andrew A. F. Hack | Chief Financial Officer | 4 de febrero de 2019 M | 0 | 0 | 0 | $0 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 28 de julio de 2026 S | 62 369 | 0 | 2 | $-15 133 |
| Bruce Eaton | EVP, Chief Business Officer | 22 de diciembre de 2021 A | 31 498 | 0 | 0 | $0 |
| Lisa Anne Michaels | EVP/Chief Medical Officer | 22 de diciembre de 2021 A | 22 675 | 0 | 0 | $0 |
| Mark S Shearman | EVP, Chief Scientific Officer | 22 de diciembre de 2021 A | 41 785 | 0 | 0 | $0 |
| Judith R Abrams | Chief Medical Officer | 28 de octubre de 2019 A | 25 000 | 0 | 0 | $0 |
| Vickesh Myer | Chief Technology Officer | 18 de marzo de 2019 M | 0 | 0 | 0 | $0 |
| Gerald Frank Cox | Chief Medical Officer | 7 de febrero de 2018 A | 4 000 | 0 | 0 | $0 |
| Elliott M. Levy | Consejero | 17 de junio de 2026 A | — | 0 | 0 | $0 |
| David Scadden | Consejero | 17 de junio de 2026 A | — | 0 | 0 | $0 |
| Bernadette Connaughton | Consejero | 17 de junio de 2026 A | — | 0 | 0 | $0 |
| Jessica Hopfield | Consejero | 17 de junio de 2026 A | 22 700 | 0 | 0 | $0 |
| Andrew Hirsch | Consejero | 17 de junio de 2026 A | — | 0 | 0 | $0 |
| Emma Reeve | Consejero | 3 de septiembre de 2021 A | — | 0 | 0 | $0 |
| Meeta Chatterjee | Consejero | 3 de junio de 2021 A | — | 0 | 0 | $0 |
| Boris Nikolic | Consejero | 15 de junio de 2018 A | 35 000 | 0 | 0 | $0 |
| Douglas G. Cole | Consejero | 17 de agosto de 2017 J | 3 171 | 0 | 0 | $0 |
| Kevin Bitterman | Consejero | 15 de junio de 2017 A | 2 797 144 | 0 | 0 | $0 |
| Alexis Borisy | Consejero | 15 de junio de 2017 A | 0 | 0 | 0 | $0 |
| John Mendlein | Consejero | 15 de junio de 2017 A | — | 0 | 0 | $0 |
| Kevin P Starr | Propietario del 10% | 6 de septiembre de 2016 S | 0 | 0 | 0 | $0 |
| bng0, LLC | Propietario del 10% | 8 de febrero de 2016 C | 2 649 572 | 0 | 0 | $0 |
| Patrick Thomas Ellinor II | — | 6 de agosto de 2026 A | — | 0 | 0 | $0 |
| Amy Parison | — | 3 de agosto de 2026 S | 14 292 | 0 | 2 | $-3 002 |
| Akshay Vaishnaw | — | 3 de junio de 2021 A | — | 0 | 0 | $0 |
| Charles Albright | — | 15 de diciembre de 2020 M | 24 907 | 0 | 0 | $0 |
| Alexandra Glucksmann | — | 15 de marzo de 2017 M | 117 788 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 1 tenencia
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Polaris Venture Partners VI, L.P. (“PVP VI”), Polaris Venture Founders’ Fund VI, L.P. (“PVPFF VI”), Polaris Venture Management Co. VI, L.L.C. (“PVM VI”), Jonathan A. Flint (“Flint”), Terrance G. McGuire (“McGuire”), Brian Chee (“Chee”), David Barrett (“Barrett”), Amir Nashat (“Nashat”), Bryce Youngren (“Youngren”) ×4 presentaciones | 18 de septiembre de 2017 | — | Presentación inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 28 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,41% | 32 319 SH | 8 de agosto de 2026 | Diario |
| GNOM · Global X Funds | 0,34% | 54 725 NS | 31 de mayo de 2026 | N-PORT |
| IWC · iShares Trust | 0,07% | 341 978 SH | 8 de agosto de 2026 | Diario |
| IBB · iShares Trust | 0,03% | 1 035 067 SH | 8 de agosto de 2026 | Diario |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,03% | 8 268 SH | 8 de agosto de 2026 | Diario |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,02% | 96 927 SH | 8 de agosto de 2026 | Diario |
| BIB · ProShares Trust | 0,02% | 3 611 NS | 31 de mayo de 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,02% | 1 527 NS | 31 de mayo de 2026 | N-PORT |
| IWO · iShares Trust | 0,02% | 823 535 SH | 8 de agosto de 2026 | Diario |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 118 938 SH | 8 de agosto de 2026 | Diario |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 575 834 SH | 8 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,01% | 461 967 SH | 8 de agosto de 2026 | Diario |
| IWM · iShares Trust | 0,01% | 2 583 050 SH | 8 de agosto de 2026 | Diario |
| RSSL · Global X Funds | 0,01% | 42 610 NS | 30 de abril de 2026 | N-PORT |
| ITWO · ProShares Trust | 0,01% | 4 633 NS | 31 de mayo de 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 476 309 NS | 31 de mayo de 2026 | N-PORT |
| UWM · ProShares Trust | 0,01% | 3 622 NS | 31 de mayo de 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 32 379 NS | 31 de mayo de 2026 | N-PORT |
| URTY · ProShares Trust | 0,00% | 3 660 NS | 31 de mayo de 2026 | N-PORT |
| IWN · iShares Trust | 0,00% | 120 119 SH | 8 de agosto de 2026 | Diario |
| HDG · ProShares Trust | 0,00% | 92 NS | 31 de mayo de 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 2 922 NS | 31 de mayo de 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 96 350 NS | 31 de mayo de 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 19 020 SH | 8 de agosto de 2026 | Diario |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 1 100 306 SH | 8 de agosto de 2026 | Diario |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4 890 144 SH | 8 de agosto de 2026 | Diario |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 9 046 SH | 8 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 7 608 SH | 8 de agosto de 2026 | Diario |